The UK’s voluntary system of revenue rebates to limit rises in medicines spending is already causing deep upset among branded drug manufacturers as clawbacks rise.
While the pharma press often focuses on R&D and drug development, the actual manufacture of drugs is an interesting space in its own right that drives many of the trends in drug pricing
It looks like Astellas has been unsuccessful in its attempt to block Pfizer's generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexis
Consumer and health organisations in the UK have written to the Trade Secretary Kemi Badenoch, saying a leaked chapter of the proposed UK-India free trade agreement (FTA) could raise the pr